Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Drug Copay Coupons topic
No spam. Unsubscribe anytime.
Committee hears competing views on drug copay coupons, transparency and accumulator rules
Summary
Rep. Emerson Levy convened a stakeholder work group and the committee heard three related bills: HB 3082 (manufacturer coupon transparency), HB 3086 (state-plan extension of prior protections) and HB 3092 (accumulator/maximizer rules). Insurers favor transparency but oppose some proposals; manufacturers warned of proprietary reporting burdens.
The committee took up a set of bills aimed at clarifying the role of manufacturer copay coupons and patient assistance in insurance cost-sharing. Representative Emerson Levy said interim stakeholder work produced proposals to collect better data on coupon programs and to extend prior 2024 protections for ACA plans to state plans.
HB 3082 would require broader reporting by drug manufacturers and greater transparency about patient assistance programs. Insurers and consumer advocates supported increased information; providers and insurers said greater transparency is needed to understand how coupons affect plan design and patient cost exposure. Pharma industry representatives, including Daria McGrew of PhRMA, opposed the bill and argued that mandatory reporting of confidential and proprietary information would exceed the existing statutory reporting thresholds and could expose sensitive commercial information.
HB 3086 would extend the coupon/accumulator protections enacted in 2024 to state programs such as the Public Employees' Benefit Board (PEBB) and OWEB (state public employer plans). HB 3092 would prohibit copay accumulator/maximizer practices for those plans, aligning state plans with prior changes affecting commercial ACA plans. Insurers including Moda and Regence said those expanded prohibitions could increase plan costs for PEBB and OWEB members and urged careful fiscal review; school boards and other public employers flagged potential rate impacts.
Stakeholders differed on whether coupon programs primarily steer patients to brand drugs with generics available; industry witnesses said less than 1% of coupons are used where generics exist. Lawmakers asked for more data on coupon usage, program duration and how manufacturers apply assistance across plan years; several witnesses recommended phased, data-driven changes rather than immediate broad reporting mandates.
